{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T03:04:46Z","timestamp":1780455886262,"version":"3.54.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T00:00:00Z","timestamp":1681344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"hong kong polytechnic university block grant","award":["1-ZE81"],"award-info":[{"award-number":["1-ZE81"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Epidemiology of infectious diseases causing febrile illness varies geographically with human attributes. Periodic institutional surveillance of clinical and microbiological profiles in adding data to updating trends, modulating pharmatherapeutics, signifying possible excessive treatments and risk of drug resistance in post-chemotherapy neutropenic fever (NF) in hematological malignancy (HM) is limited. We aimed to review institutional clinical and microbiological data and explore clinical phenotype pattern groups among data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Available data from 372 NF episodes were included. Demographics, types of malignancies, laboratory data, antimicrobial treatments and febrile-related outcome data such as predominant pathogens and microbiological diagnosed infections (MDIs) were collected. Descriptive statistics, two-step cluster analysis and non-parametric tests were employed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The occurrences of microbiological diagnosed bacterial infections (MDBIs; 20.2%) and microbiological diagnosed fungal infections (MDFIs; 19.9%) were almost equal. Gram-negative pathogens (11.8%) were comparable with gram-positive pathogens (9.9%), with gram-negative being slightly predominant. Death rate was 7.5%. Two-step cluster analysis yielded four distinct clinical phenotype pattern (cluster) groups: cluster 1 \u2018lymphomas without MDIs\u2019, cluster 2 \u2018acute leukemias MDBIs\u2019, cluster 3 \u2018acute leukemias MDFIs\u2019 and cluster 4 \u2018acute leukemias without MDIs\u2019. Considerable NF events with antibiotic prophylaxis being not identified as MDI might have cases in low-risk with non-infectious reasons causing febrile reactions that might possibly not require prophylaxis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Regular institutional surveillance with active parameter assessments to signify risk levels in the post-chemotherapy stage, even prior to the onset of fever, might be an evidence-based strategy in the management of NF in HM.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-023-08218-8","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T17:03:07Z","timestamp":1681405387000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Clinical and microbiological profiles in post-chemotherapy neutropenic fever in hematological malignancy: exploration of clinical phenotype patterns by two-step cluster analysis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0267-2962","authenticated-orcid":false,"given":"Choi Wan","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Molassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold K. K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,13]]},"reference":[{"issue":"6","key":"8218_CR1","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1200\/JCO.2012.45.8661","volume":"31","author":"CR Flowers","year":"2013","unstructured":"Flowers CR, Seidenfeld J, Bow EJ, Karten C, Gleason C, Hawley DK, Kuderer NM, Langston AA, Marr KA, Rolston KV, et al. Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2013;31(6):794\u2013810.","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"8218_CR2","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1086\/383050","volume":"39","author":"J Klastersky","year":"2004","unstructured":"Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39(Suppl 1):S32-37.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"8218_CR3","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1007\/s00520-013-1758-y","volume":"21","author":"J Klastersky","year":"2013","unstructured":"Klastersky J, Paesmans M. The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients. Support Care Cancer. 2013;21(5):1487\u201395.","journal-title":"Support Care Cancer"},{"issue":"2","key":"8218_CR4","doi-asserted-by":"publisher","first-page":"85","DOI":"10.4103\/0971-5851.116184","volume":"34","author":"AB Karanwal","year":"2013","unstructured":"Karanwal AB, Parikh BJ, Goswami P, Panchal HP, Parekh BB, Patel KB. Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: a retrospective analysis from a single center. Indian J Med Paediatr Oncol. 2013;34(2):85\u20138.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"8218_CR5","doi-asserted-by":"publisher","first-page":"596504","DOI":"10.1155\/2015\/596504","volume":"2015","author":"M Taj","year":"2015","unstructured":"Taj M, Farzana T, Shah T, Maqsood S, Ahmed SS, Shamsi TS. Clinical and microbiological profile of pathogens in febrile neutropenia in hematological malignancies: a single center prospective analysis. J Oncol. 2015;2015:596504.","journal-title":"J Oncol"},{"issue":"3","key":"8218_CR6","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1080\/21505594.2016.1156821","volume":"7","author":"G Gustinetti","year":"2016","unstructured":"Gustinetti G, Mikulska M. Bloodstream infections in neutropenic cancer patients: a practical update. Virulence. 2016;7(3):280\u201397.","journal-title":"Virulence"},{"issue":"3","key":"8218_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.4103\/0971-5851.190352","volume":"37","author":"KG Babu","year":"2016","unstructured":"Babu KG, Lokanatha D, Lakshmaiah KC, Suresh Babu MC, Jacob LA, Bhat GR, Vardhana H, Sinha M, Vijaykumar BR, Sumati BG, et al. Bloodstream infections in febrile neutropenic patients at a tertiary cancer institute in South India: a timeline of clinical and microbial trends through the years. Indian J Med Paediatr Oncol. 2016;37(3):174\u201382.","journal-title":"Indian J Med Paediatr Oncol"},{"key":"8218_CR8","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1038\/nature06536","volume":"451","author":"KE Jones","year":"2008","unstructured":"Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases. Nature. 2008;451:990.","journal-title":"Nature"},{"key":"8218_CR9","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, Langston AA, Nastoupil LJ, Rajotte M, Rolston KV, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018;36:3043\u201354.","journal-title":"J Clin Oncol"},{"issue":"3","key":"8218_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s10096-003-1084-2","volume":"23","author":"R Colodner","year":"2004","unstructured":"Colodner R, Rock W, Chazan B, Keller N, Guy N, Sakran W, Raz R. Risk factors for the development of extended-spectrum Beta-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis. 2004;23(3):163\u20137.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"6","key":"8218_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ajic.2005.03.009","volume":"33","author":"ZA Kanafani","year":"2005","unstructured":"Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum \u03b2-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control. 2005;33(6):326\u201332.","journal-title":"Am J Infect Control"},{"issue":"8","key":"8218_CR12","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1086\/319757","volume":"32","author":"E Lautenbach","year":"2001","unstructured":"Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32(8):1162\u201371.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"8218_CR13","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s10096-004-1264-8","volume":"24","author":"G Mendelson","year":"2005","unstructured":"Mendelson G, Hait V, Ben-Israel J, Gronich D, Granot E, Raz R. Prevalence and risk factors of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in an Israeli long-term care facility. Eur J Clin Microbiol Infect Dis. 2005;24(1):17\u201322.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"10","key":"8218_CR14","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa044097","volume":"353","author":"G Bucaneve","year":"2005","unstructured":"Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D\u2019Antonio D, Buelli M, Nosari AM, et al. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005;353(10):977\u201387.","journal-title":"N Engl J Med"},{"issue":"8","key":"8218_CR15","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1002\/cncr.22205","volume":"107","author":"L Leibovici","year":"2006","unstructured":"Leibovici L, Paul M, Cullen M, Bucaneve G, Gafter-Gvili A, Fraser A, Kern WV. Antibiotic prophylaxis in neutropenic patients. Cancer. 2006;107(8):1743\u201351.","journal-title":"Cancer"},{"issue":"1","key":"8218_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jinf.2017.10.009","volume":"76","author":"M Mikulska","year":"2018","unstructured":"Mikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, et al. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. J Infect. 2018;76(1):20\u201337.","journal-title":"J Infect"},{"issue":"11","key":"8218_CR17","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1007\/s00520-005-0825-4","volume":"13","author":"JA Zell","year":"2005","unstructured":"Zell JA, Chang JC. Neoplastic fever: a neglected paraneoplastic syndrome. Support Care Cancer. 2005;13(11):870\u20137.","journal-title":"Support Care Cancer"},{"issue":"11","key":"8218_CR18","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1001\/jama.2016.11764","volume":"316","author":"HD Marston","year":"2016","unstructured":"Marston HD, Dixon DM, Knisely JM, Palmore TN, Fauci AS. Antimicrobial resistance. JAMA. 2016;316(11):1193\u2013204.","journal-title":"JAMA"},{"key":"8218_CR19","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1037\/0022-006X.48.4.456","volume":"48","author":"RK Blashfield","year":"1980","unstructured":"Blashfield RK. Propositions regarding the use of cluster analysis in clinical research. J Consult Clin Psychol. 1980;48:456\u20139.","journal-title":"J Consult Clin Psychol"},{"key":"8218_CR20","volume-title":"Multivariate analysis with readings","author":"JF Hair","year":"1992","unstructured":"Hair JF, Anderson RE, Tatham RL, Black WL. Multivariate analysis with readings. New York: MacMillan; 1992."},{"issue":"3","key":"8218_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1010539514555214","volume":"27","author":"CW Chan","year":"2015","unstructured":"Chan CW, Leung SF. Lifestyle health behaviors of Hong Kong Chinese: results of a cluster analysis. Asia Pac J Public Health. 2015;27(3):293\u2013302.","journal-title":"Asia Pac J Public Health"},{"issue":"6","key":"8218_CR22","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jpainsymman.2019.12.372","volume":"59","author":"CW Chan","year":"2020","unstructured":"Chan CW, Lee PH, Molassiotis A, Lee HKK. Symptom clusters in postchemotherapy neutropenic fever in hematological malignancy: Associations among sickness behavior symptom cluster, inflammatory biomarkers of procalcitonin and C-reactive protein, and febrile measures. J Pain Symptom Manage. 2020;59(6):1204\u201311.","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"8218_CR23","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s00520-010-0993-8","volume":"19","author":"EP Hui","year":"2011","unstructured":"Hui EP, Leung LK, Poon TC, Mo F, Chan VT, Ma AT, Poon A, Hui EK, Mak SS, Lai M, et al. Prediction of outcome in cancer patients with febrile neutropenia: a prospective validation of the Multinational Association for Supportive Care in Cancer risk index in a Chinese population and comparison with the Talcott model and artificial neural network. Support Care Cancer. 2011;19(10):1625\u201335.","journal-title":"Support Care Cancer"},{"issue":"6","key":"8218_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1111\/j.1365-2354.2007.00780.x","volume":"16","author":"A Uys","year":"2007","unstructured":"Uys A, Rapoport BL, Fickl H, Meyer PWA, Anderson R. Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1\u03b2, -6, -8 and -10. Eur J Cancer Care. 2007;16(6):475\u201383.","journal-title":"Eur J Cancer Care"},{"issue":"11","key":"8218_CR25","doi-asserted-by":"publisher","first-page":"3478","DOI":"10.1128\/JCM.01737-13","volume":"51","author":"ES Theel","year":"2013","unstructured":"Theel ES, Doern CD. Beta-D-glucan testing is important for diagnosis of invasive fungal infections. J Clin Microbiol. 2013;51(11):3478\u201383.","journal-title":"J Clin Microbiol"},{"issue":"11","key":"8218_CR26","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1309\/LM8BW8QNV7NZBROG","volume":"42","author":"WF Wright","year":"2011","unstructured":"Wright WF, Overman SB, Ribes JA. (1\u20133)-\u03b2-D-Glucan Assay: a review of its laboratory and clinical application. Laboratory Medicine. 2011;42(11):679\u201385.","journal-title":"Laboratory Medicine"},{"issue":"16","key":"8218_CR27","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, et al. The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000;18(16):3038\u201351.","journal-title":"J Clin Oncol"},{"issue":"2","key":"8218_CR28","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/jdi.12398","volume":"7","author":"MC Amato","year":"2016","unstructured":"Amato MC, Pizzolanti G, Torregrossa V, Panto F, Giordano C. Phenotyping of type 2 diabetes mellitus at onset on the basis of fasting incretin tone: results of a two-step cluster analysis. J Diabetes Invest. 2016;7(2):219\u201325.","journal-title":"J Diabetes Invest"},{"issue":"1","key":"8218_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4103\/2278-330X.202565","volume":"6","author":"K Krishnamani","year":"2017","unstructured":"Krishnamani K, Gandhi L, Sadashivudu G, Raghunadharao D. Epedimiologic, clinical profile and factors affecting the outcome in febrile neutropenia. South Asian J Cancer. 2017;6(1):25\u20137.","journal-title":"South Asian J Cancer"},{"issue":"06","key":"8218_CR30","first-page":"142","volume":"09","author":"MV Bhojaraja","year":"2016","unstructured":"Bhojaraja MV, Kanakalakshmi ST, Prabhu MM, Thomas J. Clinical profile of high-risk febrile neutropenia in a tertiary care hospital. Aust Med J. 2016;09(06):142\u201351.","journal-title":"Aust Med J"},{"issue":"2","key":"8218_CR31","doi-asserted-by":"publisher","first-page":"116","DOI":"10.4103\/0974-2727.163126","volume":"7","author":"KC Lakshmaiah","year":"2015","unstructured":"Lakshmaiah KC, Malabagi AS, Govindbabu, Shetty R, Sinha M, Jayashree RS. Febrile neutropenia in hematological malignancies: Clinical and microbiological profile and outcome in high risk patients. J Lab Physicians. 2015;7(2):116\u201320.","journal-title":"J Lab Physicians"},{"issue":"4","key":"8218_CR32","first-page":"1","volume":"52","author":"MDAC Bautista","year":"2014","unstructured":"Bautista MDAC, Delgado JS, Bergantin MRG, Mancio PRL, Caguioa PB. Clinical profile and outcome of infections among adult leukemia patients with febrile neutropenia admitted at the University of Santo Tomas Hospital. Philippine J Intern Med. 2014;52(4):1\u20137.","journal-title":"Philippine J Intern Med"},{"issue":"6","key":"8218_CR33","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1365-2141.2011.08650.x","volume":"153","author":"TR Rogers","year":"2011","unstructured":"Rogers TR, Slavin MA, Donnelly JP. Antifungal prophylaxis during treatment for haematological malignancies: are we there yet? Br J Haematol. 2011;153(6):681\u201397.","journal-title":"Br J Haematol"},{"issue":"7","key":"8218_CR34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1002\/ajh.25808","volume":"95","author":"GY Kim","year":"2020","unstructured":"Kim GY, Burns J, Freyer CW, Hamilton KW, Frey NV, Gill SI, Hexner EO, Luger SM, Mangan JK, Martin ME, et al. Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. Am J Hematol. 2020;95(7):792\u20138.","journal-title":"Am J Hematol"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08218-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08218-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T17:03:42Z","timestamp":1681405422000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08218-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,13]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8218"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08218-8","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,13]]},"assertion":[{"value":"14 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the ethics committees of the Hong Kong Polytechnic University, Hong Kong; and Kowloon West Cluster Hospital Authority, Hong Kong. All participants have provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"226"}}